SEARCH

SEARCH BY CITATION

References

  • 1
    Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 28591.
  • 2
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 80915.
  • 3
    Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 45864.
  • 4
    Trousseau A. Plegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris 1865; 5: 281332.
  • 5
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 15: 110.
  • 6
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 6324.
  • 7
    Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 34848.
  • 8
    Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, Khosla SG, Rivera E. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164: 165361.
  • 9
    Mandalà M, Falanga A, Piccioli A, Prandoni P, Pogliani EM, Labianca R, Barni S; working group AIOM. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006; 59: 194204.
  • 10
    Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490505.
  • 11
    Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quéré I, Levesque H, Debourdeau P; SOR. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 2010; 73: 3146.
  • 12
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(Suppl 6): 381S453S.
  • 13
    Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(Suppl 6): 454S545S.
  • 14
    Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 41423.
  • 15
    Venous thromboembolic disease NCCN guidelines V2.2009. 2009. http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf Accessed on 8 August 2011.
  • 16
    Mandala M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations. Ann Oncol 2009; 20(Suppl 4): iv82iv84.
  • 17
    Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Lévesque H, Renaudin JM, Farge D; Working group of the SOR; French National Feberation of Cancer Centers. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009; 20: 145971.
  • 18
    Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(Suppl 6): vi8592.
  • 19
    Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 38794.
  • 20
    Noble SI, Shelley MD, Coles B, Williams SM, Wilcock A, Johnson MJ; Association for Palliative Medicine for Great Britain and Ireland. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9: 57784.
  • 21
    Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 6924.
  • 22
    Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 2024.
  • 23
    Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schünemann HJ; GRADE Working Group. Rating quality of evidence of and strength of recommandations. BMJ 2008; 336: 104951.
  • 24
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 9246.
  • 25
    Moore FD Jr, Osteen RT, Karp DD, Steele G Jr, Wilson RE. Anticoagulants, venous thromboembolism and the cancer patient. Arch Surg 1981; 116: 4057.
  • 26
    Clarke-Pearson D, Coleman R, Synan I, Creasman W. Anticoagulation therapy for VTE in patients with gynaecologic malignancy. Am J Obstet Gynecol 1983; 147: 36975.
  • 27
    Krauth D, Holden A, Knapic N, Liepman M, Ansell J. Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer 1987; 59: 9835.
  • 28
    Calligaro KD, Bergen WS, Haut MJ, Savarese RP, DeLaurentis DA. Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement. Ann Vasc Surg 1991; 5: 1869.
  • 29
    Chan A, Woodruff RK. Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Aust N Z J Med 1992; 22: 11922.
  • 30
    Debourdeau P, Meyer G, Sayeg H, Marjanovic Z, Bastit L, Cabane J, Merrer J, Extra JM, Farge D. Traitement anticoagulant classique de la maladie thromboembolique veineuse chez les patients cancéreux. A propos d’une série rétrospective de 71 patients. Rev Med Int 1996; 17: 20712.
  • 31
    Harrington KJ, Bateman AR, Syrigos KN, Rintoul R, Bhidayasiri R, McCormack M, Thomas H. Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis. Ann Oncol 1997; 8: 66973.
  • 32
    Bona RD, Hickey AD, Wallace DM. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am J Clin Oncol 2000; 23: 713.
  • 33
    Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 307883.
  • 34
    Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D’Angelo A, Pengo V, Moia M, Coccheri S. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000; 84: 80510.
  • 35
    Vucic N, Ostojic R, Svircic T. Treatment of deep vein thrombosis with oral anticoagulants in patients with malignancy: prospective cohort study. Croat Med J 2002; 43: 296300.
  • 36
    Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 106272.
  • 37
    van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost 2009; 101: 7629.
  • 38
    Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 172935.
  • 39
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 14653.
  • 40
    Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J; ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 38996.
  • 41
    Romera A, Cairols MA, Vila-Coll R, Martí X, Colomé E, Bonell A, Lapiedra O. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 37: 34956.
  • 42
    Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins, a meta-analysis. Arch Intern Med 1995; 155: 6017.
  • 43
    Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 26977.
  • 44
    Hettiarachchi R, Prins M, Lensing A, Büller HR. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med 1998; 4: 2205.
  • 45
    Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 8009.
  • 46
    Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 1818.
  • 47
    Rocha E, Martínez-González MA, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica 2000; 85: 93542.
  • 48
    Quinlan D, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140: 17583.
  • 49
    Mismetti P, Quenet S, Levine M, Merli G, Decousus H, Derobert E, Laporte S. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 2005; 128: 220310.
  • 50
    Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Bdair F, Schünemann HJ. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer 2008; 113: 168594.
  • 51
    Akl EA, Vasireddi SR, Gunukula S, Barba M, Sperati F, Terrenato I, Muti P, Schünemann H. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Review). Cochrane Database Syst Rev 2011; 6: CD006649.
  • 52
    Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer. Am Heart J 1997; 134: 6037.
  • 53
    Cohen J, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991; 109: 125.
  • 54
    Cohen J, Grella L, Citron M. Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer. Cancer 1992; 70: 19936.
  • 55
    Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993; 43: 11114.
  • 56
    Hubbard K, Roehm J, Abbruzzese JL. The Bird’s Nest Filter. An alternative to long-term oral anticoagulation in patients with advanced malignancies. Am J Clin Oncol 1994; 17: 1157.
  • 57
    Schiff D, De Angelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994; 73: 4938.
  • 58
    Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: indications and outcome. J Clin Oncol 1996; 14: 6527.
  • 59
    Greenfield L, Proctor M, Saluja A. Clinical results of Greenfield filter use in patients with cancer. Cardiovasc Surg 1997; 5: 1459.
  • 60
    Ihnat DM, Mills JL, Hughes JD, Gentile AT, Berman SS, Westerband A. Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? J Vasc Surg 1998; 28: 8007.
  • 61
    Schleich JM, Morla O, Laurent M, Langella B, Chaperon J, Almange C. Long-term follow-up of percutaneous vena cava filters: a prospective study in 100 consecutive patients. Eur J Vasc Endovasc Surg 2001; 21: 4507.
  • 62
    Jarrett BP, Dougherty MJ, Calligaro KD. Inferior vena cava filters in malignant disease. J Vasc Surg 2002; 36: 7047.
  • 63
    Wallace MJ, Jean JL, Gupta S, Eapen GA, Johnson MM, Ahrar K, Madoff DC, Morello FA, Murthy R, Hicks ME. Use of inferior vena caval filters and survival in patients with malignancy. Cancer 2004; 101: 19027.
  • 64
    Zerati AE, Wolosker N, Yazbek G, Langer M, Nishinari K. Vena cava filters in cancer patients: experience with 50 patients. Clinics (Sao Paulo, Brazil) 2005; 60: 3616.
  • 65
    Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U. Inferior vena cava filter placement in late-stage cancer. Vasc Endovasc Surg 2006; 40: 28794.
  • 66
    Monreal M, Zacharski L, Jiménez JA, Roncales J, Vilaseca B. Fixed dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004; 2: 13115.
  • 67
    López-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martinez A, Lozano G, Romero A. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001; 33: 7790.
  • 68
    Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003; 1: 190613.
  • 69
    Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalà M, Papaldo P, Fabi A, Ciccarese M, Cuppone F, Cecere FL, Nuzzo C, Terzoli E, Cognetti F. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest 2006; 130: 180816.
  • 70
    Louzada M, Majeed H, Wells P. Efficacy of low- molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009; 123: 83744.
  • 71
    Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann HJ. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008; 2: CD006650.
  • 72
    Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2008; 27: 21.
  • 73
    van Doormaal FF, Cohen AT, Davidson BL, Decousus H, Gallus AS, Gent M, Piovella F, Prins MH, Raskob GE, Büller HR. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: A subgroup analysis of the VANGOGH-DVT trial. Thromb Haemost 2010; 104: 8691.
  • 74
    Siragusa S, Malato A, Mascheroni D, Ageno W, Bucherini E, Spadaro P, Imberti D, Saccullo G, Rotondo S, Santoro R, Pierpaolo di Micco, Oriana V, Urban O, Recchia F, D’Alessio A, GalluccI P, Ghirarduzzi A, Cormaci O, Caracciolo C, et al. The optimal duration of anticoagulant therapy In patients with cancer-related deep vein thrombosis: the advantage of using residual vein thrombosis (the Cancer-DACUS Study). Blood 2010; 116: 190.
  • 75
    Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7: 7605.
  • 76
    Shukla PJ, Siddachari R, Ahire S, Arya S, Ramani S, Barreto SG, Gupta S, Shrikhande SV, Jagannath P, Desouza LJ. Postoperative deep vein thrombosis in patients with colorectal cancer. Ind J Gastroenterol 2008; 27: 713.
  • 77
    Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 91330.
  • 78
    Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol 2007; 105: 8139.
  • 79
    Oates-Whitehead R, D’Angelo A, Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. Cochrane Database Syst Rev 2003; 4: CD003679.
  • 80
    ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099103.
  • 81
    Baykal C, Al A, Demirtaş E, Ayhan A. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol 2001; 22: 12730.
  • 82
    McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM, Silverman RE, Atkinson KG, Burnstein M, Marshall JC, Burul CJ, Anderson DR, Ross T, Wilson SR, Barton P; Canadian Colorectal Surgery DVT Prophylaxis Trial investigators. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery. Ann Surg 2001; 233: 43844.
  • 83
    Akl EA, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P, Cook DJ, Schünemann HJ. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 2008; 168: 12619.
  • 84
    Agnelli G, Bergqvist D, Cohen A, Gallus AS, Gent M; PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 121220.
  • 85
    Simonneau G, Laporte S, Mismetti P, Derlon A, Samii K, Samama CM, Bergman JF; FX140 Study Investigators. A randomized study comparing the efficacy and safety of nadroparin 2850 IU. J Thromb Haemost 2006; 4: 1693700.
  • 86
    Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallböök T, Hedberg M, Horn A, Kelty E, Kvitting P, Lindhagen A, Ljungström KG, Mätzsch T, Risberg B, Syk I, Törngren S, Wellander E, Örtenwall P. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 vs 5000 Xa IU in 2070 patients. Br J Surg 1995; 82: 496501.
  • 87
    Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F II; ENOXACAN Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 97580.
  • 88
    Lausen I, Jensen R, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, Raaschou HO, Wille-Jørgensen P. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 1998; 164: 65763.
  • 89
    Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, Nielsen JD, Horn A, Mohn AC, Sømod L, Olsen B; FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4: 238490.
  • 90
    Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P; CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8: 12239.
  • 91
    Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schünemann HJ. Extended perioperative thromboprophylaxis in patients with cancer. Thromb Haemost 2008; 100: 117680.
  • 92
    Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obst Gynecol 2001; 98: 98995.
  • 93
    Turpie AG, Hirsh J, Gent M, Julian D, Johnson J. Prevention of deep vein thrombosis in potential neurosurgical patients; a randomized trial comparing graduated compression stockings plus intermittent pneumatic compression with control. Arch Med Intern 1989; 149: 679681.
  • 94
    Dickinson L, Miller L, Patel C, Gupta S. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998; 43: 107481.
  • 95
    Collen JF, Jackson JL, Shorr AF, Moores LK. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest 2008; 134: 23749.
  • 96
    Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996; 76: 52934.
  • 97
    Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 1996; 26: 12739.
  • 98
    Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The PRIME Study Group. Haemostasis 1996; 26(suppl 2): 4956.
  • 99
    Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW; THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003; 145: 61421.
  • 100
    Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 15964.
  • 101
    Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793800.
  • 102
    Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Circulation 2004; 110: 8749.
  • 103
    Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 3259.
  • 104
    Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 50: 298303.
  • 105
    Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, Anderson R, Cherrick I, Desai S, Mahoney D, McCusker P, Chait P, Abdolell M, de Veber G, Mikulis D. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Thromb Haemost 2003; 90: 23544.
  • 106
    Riess H, Pelzer U, Deutschinoff G. PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. ASCO 2009, abstract LBA4506.
  • 107
    Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48: 128392.
  • 108
    Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, Melzer N, Kakkar AK; TOPIC Investigators. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012; 18: 15965.
  • 109
    Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 9439.
  • 110
    Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8: 195965.
  • 111
    Verso M, Gussoni G, Agnelli G. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 2010; 8: 164951.
  • 112
    Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, van Rhee F, Fassas A, Fink L, Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 71521.
  • 113
    Ikhlaque N, Seshadri V, Kathula S, Baumann MA. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006; 81: 4202.
  • 114
    Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 10: 29.
  • 115
    El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. Thromb Haemost 2007; 97: 10316.
  • 116
    Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K; Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008; 34: 44252.
  • 117
    Schmidt F, Faul C, Dichgans J, Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol 2002; 249: 140912.
  • 118
    Altschuler E, Moosa H, Selker RG, Vertosick FT Jr. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 1990; 27: 746.
  • 119
    Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg 1978; 49: 37881.
  • 120
    Constantini S, Kanner A, Friedman A, Shoshan Y, Israel Z, Ashkenazi E, Gertel M, Even A, Shevach Y, Shalit M, Umansky F, Rappaport ZH. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg 2001; 94: 91821.
  • 121
    Macdonald RL, Amidei C, Baron J, Weir B, Brown F, Erickson RK, Hekmatpanah J, Frim D. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol 2003; 59: 36372.
  • 122
    Melon E, Keravel Y, Gaston A, Huet Y, Combes S, the NEURONOX Group. Deep venous thrombosis prophylaxis by LMWH in neurosurgical patients. Anesthesiology 1991; 75: A214.
  • 123
    Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d’Azemar P, Büller HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AG, Haley S, Sicurella A, Gent M. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996; 75: 2338.
  • 124
    Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, Beltrametti C, Damiani M, Andrioli GC, Pugliese R, Iorio A, Brambilla G. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339: 805.
  • 125
    Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002; 122: 19337.
  • 126
    Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000; 160: 232732.